A cash-burning single-product biotech where analysts project more than doubling from current levels, but persistent earnings misses, deeply negative free cash flow, and a heavily defensive options market reflect the substantial execution risk that stands between the current price and the upside scenario.
Thesis pillars
- Catastrophic Cash Burn No Moat→Stable
- Single Product Concentration Binary Risk↑Improving
- Persistent Earnings Miss Track Record↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $83.66: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Elevated put/call ratio: 2.86; Below-average business quality; Rich valuation.
Crinetics Pharmaceuticals develops small-molecule therapies targeting peptide hormone GPCRs for endocrine diseases. PALSONIFY (paltusotine), the first once-daily oral acromegaly treatment, received FDA approval September 25, 2025, and became commercially available in the U.S. in... Read more
Sell if holding. Engine safety override at $83.66: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Elevated put/call ratio: 2.86; Below-average business quality; Rich valuation. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 4.5/10, moderate confidence.
Passes 5/9 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: speculative.
About Crinetics Pharmaceuticals, Inc.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals received FDA approval for PALSONIFY (paltusotine) on September 25, 2025, making it the first once-daily oral somatostatin receptor ligand for acromegaly, a rare pituitary disorder affecting approximately 11,500 actively managed patients in the U.S. Atumelnant is in Phase 3 development for congenital adrenal hyperplasia (CALM-CAH first patient randomized December 2025) and plans a Phase 2/3 study in ACTH-dependent Cushing's disease in the first half of 2026. CRN09682, a novel drug conjugate targeting SST2-expressing tumors, received its first patient dose in November 2025.
Crinetics generates commercial revenue from PALSONIFY through specialty pharmacy distribution, targeting the estimated 11,500 actively managed U.S. acromegaly patients using a specialized commercial organization focused on endocrinologists and pituitary surgeons. PALSONIFY holds FDA orphan drug designation for acromegaly, and in February 2026 the EMA's Committee for Human Medicinal Products adopted a positive opinion recommending EU marketing authorization, with a potential European Commission decision in the first half of 2026. Commercialization in Japan is licensed exclusively to SKK. Manufacturing relies on third-party contract manufacturers. Paltusotine is also in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors (CAREFNDR study, first patient November 2025), which if approved would address an estimated 18,000-34,000 potential U.S. candidates.
Show full overview
Crinetics had an accumulated deficit of $1.4 billion at December 31, 2025, with the 10-K identifying paltusotine as the primary financial dependency of the business. The Phase 3 CALM-CAH and Phase 3 CAREFNDR trials represent binary readouts that, if unfavorable, could impair the company's path to profitability. Crinetics may need to seek additional financing through public or private equity or debt depending on clinical outcomes and operating plans, as disclosed in the liquidity discussion of the 10-K.
See also: Healthcare · Biotechnology
From Crinetics Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-31Recent Developments — Crinetics Pharmaceuticals, Inc.
Latest news
- NEWS UBS Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85 — benzinga Jul 28, 2026 negative
- NEWS These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why — benzinga Jul 21, 2026 positive
- NEWS Benzinga Bulls and Bears: Penguin Solutions, Draftkings, Palantir — And Stocks End Week With Solid Gains — benzinga Jul 11, 2026 positive
- NEWS Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’ — benzinga Jul 9, 2026 neutral
- NEWS Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today — benzinga Jul 8, 2026 positive
Generated 2026-07-31T01:53:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPALSONIFY (paltusotine)10-K Item 1A: 'We currently primarily depend on the success of paltusotine, approved as PALSONIFY in the U.S.'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02MEDIUMJeff Knight, Chief Development and Operating Officer, notified Crinetics of his resignation effective on or about April 10, 2026, to pursue another opportunity. No disagreement cited. All managerial responsibilities and direct reports to be reassigned to executive leadership team.SEC filing →
- 2026-04-10Item 5.02MEDIUMJeff Knight's resignation as Chief Development and Operating Officer became effective April 10, 2026. Company entered Independent Consultant Agreement with Knight for transitional services at $400/hour (up to 20 hours/month) through April 10, 2027.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $83.66: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Elevated put/call ratio: 2.86; Below-average business quality; Rich valuation. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $83.23. Score 4.5/10, moderate confidence.
Take-profit target: $82.32 (-11.1% upside). Prior stop was $83.23. Stop-loss: $83.23.
Concentration risk — Product: PALSONIFY (paltusotine); Target reached (-11.1% upside); Quality below floor (1.9 < 4.0).
Crinetics Pharmaceuticals, Inc. trades at a P/E of N/A (forward -20.6). TrendMatrix value score: 3.0/10. Verdict: Sell.
22 analysts cover CRNX with a consensus score of 4.2/5. Average price target: $86.
What does Crinetics Pharmaceuticals, Inc. do?Crinetics Pharmaceuticals develops small-molecule therapies targeting peptide hormone GPCRs for endocrine diseases....
Crinetics Pharmaceuticals develops small-molecule therapies targeting peptide hormone GPCRs for endocrine diseases. PALSONIFY (paltusotine), the first once-daily oral acromegaly treatment, received FDA approval September 25, 2025, and became commercially available in the U.S. in October 2025. Atumelnant for congenital adrenal hyperplasia and CRN09682 for SST2-expressing tumors are in active clinical development.